Treatment Outcomes and Adverse Events of a Delamanid-Based All-Oral Regimen in Children with Drug-Resistant Tuberculosis
Journal of Pediatric Pulmonology · 2026-05 · 5 (2) · 45-49
DOI: 10.4103/jopp.jopp_37_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pediatric Pulmonology, online erschienen am 13.08.2026. Verfasst von Sushant Mane und 4 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Patientensicherheit, Kinderkrankenpflege
Abstract (Originalsprache)
Background
The emergence of drug-resistant tuberculosis (DR-TB), particularly multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB), presents a significant challenge in pediatric populations. Delamanid (DLM), a novel nitro-dihydro-imidazo-oxazole, offers promise for all-oral, injectable-free regimens. This study evaluated the outcomes and safety of a DLM-based all-oral regimen in children with DR-TB. Materials and Methods: This prospective, observational study was conducted over 1.5 years. Children aged 6–18 years with confirmed or probable DR-TB (MDR, preextensively drug-resistant [pre-XDR], or XDR) were enrolled. Participants received a DLM-based regimen as per National Tuberculosis Elimination Programme (NTEP) guidelines (50 mg twice daily [BID] for 6–11 years; 100 mg BID for 12–18 years) alongside an optimized background regimen. Primary outcomes were treatment success (cured or completed). Secondary outcomes assessed adverse drug reactions (ADRs) graded as per Common Terminology Criteria for Adverse Events version 5.0.
Results
Sixty children were enrolled with a mean (±SD) age of 13.48 (±2.69) years and a female predominance of 71.7%. Resistance patterns were as follows: MDR-TB (33.33%), pre-XDR-TB (51.67%), and XDR-TB (15%). Disease sites included pulmonary (38.34%), extrapulmonary (33.33%), and disseminated (28.33%). Overall treatment success was 91.67% (45% cured and 46.67% completed treatment). Mortality was 8.33% ( n = 5) and was associated with disseminated disease and advanced resistance. ADRs occurred in 80% of patients, primarily gastrointestinal symptoms (60%) and skin pigmentation (38.33%), mostly Grade 1/2. DLM-specific corrected QT interval prolongation occurred in 8.33% of patients (all Grade 1, manageable with monitoring). Mortality was not significantly correlated with nutritional status or Bacillus Calmette–Guérin vaccination.
Conclusion
A DLM-based all-oral regimen is effective and well-tolerated for treating children with DR-TB, achieving excellent treatment success rates. The manageable safety profile, dominated by low-grade ADRs, supports its use as a core agent in pediatric DR-TB therapy, facilitating better compliance than injectable-containing regimens.
Zitieren
APA
Mane, S., Shirsat, P., Pustake, M., Charania, K., & Kukade, R. (2026). Treatment Outcomes and Adverse Events of a Delamanid-Based All-Oral Regimen in Children with Drug-Resistant Tuberculosis. Journal of Pediatric Pulmonology, 5(2), 45-49. https://doi.org/10.4103/jopp.jopp_37_25
Vancouver
Mane S, Shirsat P, Pustake M, Charania K, Kukade R. Treatment Outcomes and Adverse Events of a Delamanid-Based All-Oral Regimen in Children with Drug-Resistant Tuberculosis. Journal of Pediatric Pulmonology. 2026;5(2):45-49. doi:10.4103/jopp.jopp_37_25
BibTeX
@article{Mane2026,
author = {Mane, Sushant and Shirsat, Pranita and Pustake, Manas and Charania, Kaif and Kukade, Rohit},
title = {Treatment Outcomes and Adverse Events of a Delamanid-Based All-Oral Regimen in Children with Drug-Resistant Tuberculosis},
journal = {Journal of Pediatric Pulmonology},
year = {2026},
volume = {5},
number = {2},
pages = {45--49},
doi = {10.4103/jopp.jopp_37_25}
}
EUVIMED